JP2004536783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536783A5 JP2004536783A5 JP2002552127A JP2002552127A JP2004536783A5 JP 2004536783 A5 JP2004536783 A5 JP 2004536783A5 JP 2002552127 A JP2002552127 A JP 2002552127A JP 2002552127 A JP2002552127 A JP 2002552127A JP 2004536783 A5 JP2004536783 A5 JP 2004536783A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- immune response
- sequence
- signal
- sequence homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 230000028993 immune response Effects 0.000 claims 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 230000029069 type 2 immune response Effects 0.000 claims 2
- QUBNFZFTFXTLKH-UHFFFAOYSA-N 2-aminododecanoic acid Chemical compound CCCCCCCCCCC(N)C(O)=O QUBNFZFTFXTLKH-UHFFFAOYSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- 229940000635 beta-alanine Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- PBLZLIFKVPJDCO-UHFFFAOYSA-N omega-Aminododecanoic acid Natural products NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/739,466 US7786257B2 (en) | 2000-12-18 | 2000-12-18 | Signal-1/signal-2 bifunctional peptide inhibitors |
| PCT/US2001/048632 WO2002050250A2 (en) | 2000-12-18 | 2001-12-17 | Signal-1/signal-2 bifunctional peptide inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536783A JP2004536783A (ja) | 2004-12-09 |
| JP2004536783A5 true JP2004536783A5 (enExample) | 2005-06-09 |
Family
ID=24972431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002552127A Pending JP2004536783A (ja) | 2000-12-18 | 2001-12-17 | シグナル−１／シグナル−２二官能性ペプチド阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7786257B2 (enExample) |
| EP (2) | EP1404362B1 (enExample) |
| JP (1) | JP2004536783A (enExample) |
| AT (1) | ATE400293T1 (enExample) |
| AU (1) | AU2002230911A1 (enExample) |
| CA (1) | CA2432767A1 (enExample) |
| DE (1) | DE60134791D1 (enExample) |
| WO (1) | WO2002050250A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188218B2 (en) | 2006-10-27 | 2012-05-29 | University Of Kansas | Bi-functional peptides for multiple sclerosis treatment and diagnosis |
| US8735154B2 (en) | 2006-10-30 | 2014-05-27 | The University Of Kansas | Templated islet cells and small islet cell clusters for diabetes treatment |
| US8016856B2 (en) * | 2006-11-30 | 2011-09-13 | Cook Medical Technologies Llc | Removable handle for medical device |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| ES2402956T3 (es) | 2007-08-15 | 2013-05-10 | Circassia Limited | Péptido con formación de dímeros reducida |
| EP2211889B1 (en) * | 2007-10-25 | 2014-08-20 | The Scripps Research Institute | Antibody-mediated disruption of quorum sensing in bacteria |
| DE102009040716B4 (de) * | 2009-09-10 | 2011-07-14 | Miltenyi Biotec GmbH, 51429 | Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen |
| WO2011163568A1 (en) | 2010-06-24 | 2011-12-29 | University Of Kansas | Conjugates comprising an n-oxime bond and associated methods |
| WO2013016544A2 (en) | 2011-07-27 | 2013-01-31 | University Of Kansas | Templated islet cells and small islet cell clusters for diabetes treatment |
| CN105708834A (zh) * | 2011-10-18 | 2016-06-29 | 株式会社爱茉莉太平洋 | 包含丁香脂素的sirt1活化剂 |
| US11919939B2 (en) * | 2017-05-23 | 2024-03-05 | Université De Genève | Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| EP0576842B1 (de) * | 1992-06-11 | 2002-10-16 | MERCK PATENT GmbH | Verfahren und Mittel zum Nachweis von Listerien |
| US5540926A (en) | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| ATE417112T1 (de) | 1997-03-27 | 2008-12-15 | Csl Ltd | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen |
| US7118751B1 (en) * | 1999-10-14 | 2006-10-10 | Trubion Pharmaceuticals, Inc. | DNA vaccines encoding antigen linked to a domain that binds CD40 |
-
2000
- 2000-12-18 US US09/739,466 patent/US7786257B2/en not_active Expired - Fee Related
-
2001
- 2001-12-17 EP EP01991168A patent/EP1404362B1/en not_active Expired - Lifetime
- 2001-12-17 AU AU2002230911A patent/AU2002230911A1/en not_active Abandoned
- 2001-12-17 DE DE60134791T patent/DE60134791D1/de not_active Expired - Fee Related
- 2001-12-17 EP EP07014573A patent/EP1932539A3/en not_active Withdrawn
- 2001-12-17 AT AT01991168T patent/ATE400293T1/de not_active IP Right Cessation
- 2001-12-17 WO PCT/US2001/048632 patent/WO2002050250A2/en not_active Ceased
- 2001-12-17 CA CA002432767A patent/CA2432767A1/en not_active Abandoned
- 2001-12-17 JP JP2002552127A patent/JP2004536783A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536783A5 (enExample) | ||
| JP2005514030A5 (enExample) | ||
| Mochly-Rosen et al. | Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site | |
| JP2004248677A5 (enExample) | ||
| Burioni et al. | Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments | |
| CA2406240C (en) | Hcv anti-core monoclonal antibodies | |
| JP2004504063A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2005518456A (ja) | Ｐｎａ連結要素または機能的要素を含むナノ構造 | |
| JP2005519580A5 (enExample) | ||
| NZ507378A (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| EP0896583B1 (en) | Use of peptide fragments derived from osp-c for diagnostic methods | |
| JPH06510192A (ja) | 推定上のｈｃｖ ｅ２／ｎｓ１蛋白に対するモノクローナル抗体およびその使用方法 | |
| WO1995021922A3 (en) | Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use | |
| WO1999003987A3 (fr) | Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie | |
| JP2019535321A5 (enExample) | ||
| NZ547629A (en) | Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb | |
| JP2002517193A5 (enExample) | ||
| US6716574B2 (en) | Osp-C derived peptide fragments | |
| JPWO2021016724A5 (enExample) | ||
| JP2017536821A5 (enExample) | ||
| JP2005512016A5 (enExample) | ||
| JP2006503088A5 (enExample) | ||
| JPH1066585A5 (enExample) | ||
| JP2002513802A5 (enExample) |